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Abstract
Genetic, biochemical, and animal model studies strongly suggest a central role for a-synuclein in the pathogenesis of
Parkinson’s disease. a-synuclein lacks a signal peptide sequence and has thus been considered a cytosolic protein. Recent
data has suggested that the protein may be released from cells via a non-classical secretory pathway and may therefore
exert paracrine effects in the extracellular environment. However, proof that a-synuclein is actually secreted into the brain
extracellular space in vivo has not been obtained. We developed a novel highly sensitive ELISA in conjugation with an in
vivo microdialysis technique to measure a-synuclein in brain interstitial fluid. We show for the first time that a-synuclein is
readily detected in the interstitial fluid of both a-synuclein transgenic mice and human patients with traumatic brain injury.
Our data suggest that a-synuclein is physiologically secreted by neurons in vivo. This interstitial fluid pool of the protein
may have a role in the propagation of synuclein pathology and progression of Parkinson’s disease.
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Introduction
a-Synuclein is linked genetically and biochemically to Parkin-
son’s Disease (PD) [1]. a-Synuclein is the principal constituent of
proteinaceous inclusions termed Lewy Bodies, the pathological
hallmark of PD [2]. Point mutations as well as multiplications in
the locus encoding for a-synuclein are linked with familial cases of
PD [3,4,5]. The mechanism of involvement of a-synuclein in PD is
not well understood, although there is evidence that abnormal
folding plays a critical role in the pathogenesis of the disease and
that the toxic a-synuclein species may be oligomeric intermediates
[6,7]. Until recently, a-synuclein was considered to exert its
pathogenic effects in the cytoplasm of the cells. However, it was
demonstrated that soluble monomeric and oligomeric forms of a-
synuclein are present in human cerebrospinal fluid (CSF) and
blood plasma of healthy and diseased individuals. [8,9]. These
results suggest that the physiological as well as the aberrant actions
of a-synuclein can extend to the extracellular space and
neighboring cells. However, the species and mechanisms involved
in such actions have not been elucidated.
We recently showed that a-synuclein can be physiologically
released to the extracellular space of overexpressing cells in a
calcium dependent manner and partly via a mechanism that
involves exosomes [10]. Extracellular a-synuclein can be toxic to
recipient neurons [10,11]. In support for a pathogenic role for
extracellular a-synuclein, recent reports show that a-synuclein
aggregates released from neuronal cells can be transferred to
neighboring neurons forming Lewy-like inclusions [12], providing
mechanistic basis for the development of Lewy pathology in
normal mesencephalic transplants in PD patients [13,14]. To this
end, recent data demonstrated in vivo transfer of a-synuclein to
dopaminergic neurons grafted to the striatum of transgenic mice
overexpressing human a-synuclein [15] bolstering the hypothesis
of a cell-to-cell spread of a-synuclein pathology. Interestingly,
Danzer et al., recently demonstrated the uptake of secreted a-
synuclein oligomers by neurons and their detrimental effect on
neuronal survival [16].
Still, despite these exciting findings, the evidence for extracel-
lular a-synuclein in the brain has been controversial and not yet
fully verified and relies primarily on its presence in human CSF. It
is therefore crucial to examine whether a-synuclein is actually
released at biologically meaningful concentrations in an in vivo
context and in the absence of any evidence of cell death.
Understanding the mechanisms which underlie the regulation of
a-synuclein secretion in normal physiology may provide unique
insights into new unidentified factors in the progression and/or
pathogenesis of PD.
In the current study, we have developed a novel highly sensitive
ELISA and employed microdialysis to investigate the presence of
a-synuclein in the interstitial fluid (ISF) of awake adult A53T a-
synuclein transgenic mice [17] that develop a-synuclein oligomer-
ization and in human subjects with severe brain injury who
undergo microdialysis. Our data show that a-synuclein is normally
present in the brain parenchyma. As such, it may have as yet
unidentified physiological and pathogenic roles in the extracellular
space.
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Animals
For in vivo microdialysis experiments we used male homozygous
transgenic (Tg) C57BI/C3H mice expressing human A53T a-
synuclein under the control of the prion promoter (Jackson
Laboratory, Bar Harbor, Main). The generation and phenotype of
these mice has been previously described [17]. Mice were used at
8–12 months of age. Wild type (WT) littermates and C57BL6/
JOlaHsd synuclein null mice (stain number Harlan Laboratories)
of the same sex and age were used as controls to verify signal
specificity [18]. Animals were housed in the animal facility of the
Biomedical Research Foundation of the Academy of Athens
(BRFAA) in a room with a controlled light-dark cycle (12 hours
light-12 hours dark) and free access to food and water.
In vitro microdialysis
In vitro microdialysis experiments wereperformed in human CSF.
For in vitro recovery, low molecular weight secreted a-synuclein
species from SHSY5Y overexpressing the WT form of the protein
were also used as an alternative source of a-synuclein (prepared as
described in [10]). In some experiments, CSF was spiked with
recombinant a-synuclein (gift from H. A. Lashuel, EPFL, Lausanne,
Switzerland). Lyophilized a-synuclein was reconstituted in PBS,
filtered through a 0.2 mm filter and then through a 100 kDa cut off
filter (Millipore) to yield pure monomeric protein.
Theprobesusedformousemicrodialysis(CMA-12custommade,
2 mm length, 0.5 mm diameter, 100 kDa cut-off) were connected
to a CMA 402 syringe pump through teflon (FEP) tubing (inner
diameter 0.12 mm; 1.2 ml/100 mm, CMA). The probes used for
human microdialysis (CMA 71, 30 mm length, 0.5 mm diameter,
100 kDacut-off)wereconnected toa CMA106 syringepump (fixed
flow rate 0.3 ml/min). Probes were first washed with artificial CSF
(CNS perfusion fluid, CMA) containing 0.15% BSA (Sigma)
previously filtered through a 100 kDa cut off filter (Millipore).
In vivo mice microdialysis
Guide cannulas were stereotaxically implanted in the striatum
under isoflurane anesthesia (4–2.5%) as previously described [19].
Animals were kept anesthetized during the whole procedure.
Breathing was kept stable using an oxygen / air ratio of 0.5. Bore
holes were made above the right striatum according to the mouse
atlas of Paxinos and Franklin (coordinates, AP=+0.5 mm,
ML=22.2 mm, DV=22.4 mm). CMA 12 guide cannulas were
inserted and fixed to the skull with stainless steel screws and dental
cement. Mice were removed from the stereotaxic device and
allowed to recover in individual cages. 72–96 hrs after surgery,
mice were moved to the microdialysis cage. During microdialysis,
mice were awake and had free access to food and water (CMA 120
System for Freely Moving Animals). CMA 12 custom made probes
were manually inserted and connected to the CMA 402 syringe
pump with a constant flow rate of 0.6 ml/min. Prior to sample
collection, the probe was allowed to equilibrate for at least 2 hrs
with the same flow rate. Samples were collected bihourly for 6 hrs
using a CMA 170 refrigerated fraction collector and stored at
280uC until analyzed by ELISA. At the end of the experiment,
the brain was excised, fixed in 4% paraformaldehyde at 4uC and
analyzed for probe placement with 2% Coomassie blue staining.
All efforts were made to minimize animal suffering and to reduce
the number of the animals used, according to the European
Communities Council Directive (86/609/EEC) guidelines for the
care and use of laboratory animals. All animal experiments were
approved by the Institutional Animal Care and Use Committee of
BRFAA (permit number A.05.1/6/02-07).
Histochemical processing
Mice were deeply anesthetized by an overdose of pentobarbital
and perfused transcardially first with 30 ml PBS and then with
30 ml of ice-cold 4% paraformaldehyde in PBS. Brains were
quickly removed, post-fixed in the same fixative for 16 hours at
4uC and cryoprotected first in 15% sucrose in PBS for 24 h and
then in 30% sucrose in PBS for 24 h at 4uC. Finally, brains were
frozen at 245uC and stored at 280uC until sectioning. For each
mouse, free-floating cryostat-cut sections (30 mm) were collected
using a Bright cryostat at 225uC at the levels of striatum (AP,
0.2 mm from bregma).
Tissue double labeling
For double-fluorescence labelling, 30 mm free-floating sections
were rinsed in three changes of PBS for 5 min each and then
blocked for 60 min in 2% NGS in PBS containing 0.1% Triton-X
(blocking buffer). Sections were then incubated with anti-NeuN
antibody (mouse IgG1, 1:250, Millipore) and anti-tyrosine
hydroxylase (TH) antibody (rabbit IgG, 1:1000, Chemicon) in
blocking buffer for 16 hours at 4uC. Sections were again washed as
above and then transferred to a mixture of Cy3-conjugated anti-
mouse and Cy2 secondary–conjugated anti-rabbit antibodies
(Jackson ImmunoResearch), each diluted 1:100 in blocking buffer,
for 60 min at room temperature. Sections were first rinsed three
times in PBS for 5 min each, then in H2O for 2 min, and finally
sections were mounted on Superfrost plus slides (VWR) and air-
dried for 16 hours at 37uC. For Fluoro-Jade C staining, NeuN-
stained sections were rehydrated for 2 min in H2O and then
transferred to a 0.06% potassium permanganate solution for
20 min. Sections were rinsed once more in H2O for 2 min and
transferred to 0.0002% Fluoro-Jade C in 0.1% acetic acid for
10 min. Following staining, slides were washed three times in
H2O, air-dried for 16 hours at 37uC, xylene-cleared and cover-
slipped with DPX. Images were obtained in either a Leica
DMRA2 upright microscope or in a Leica SP5-II confocal
microscope.
Human CSF samples
CSF samples were obtained from Normal Pressure Hydroceph-
alus patients undergoing ventriculoperitoneal shunting in Evagge-
lismos Hospital (Athens, Greece). All subjects were otherwise
healthy and in a good general condition. CSF was collected upon
insertion of the ventricular catheter (initial flow discarded to avoid
blood contamination). The study was approved by the Evagge-
lismos Hospital Bioethics Board. CSF collection was carried out
with the informed written consent of all patients.
In vivo human microdialysis
Human microdialysis samples were obtained from patients
(male and female; 30–60 years old) suffering from severe head
injury (Glascow Coma Scale #8 following cardiopulmonary
resuscitation) and admitted to the ICU. All patients had an
abnormal admitting CT scan and microdialysis was part of their
routine monitoring. Their past history was unremarkable and
coagulation normal. Approval for using the microdialysis samples
in the current study was obtained from the Evaggelismos Hospital
Bioethics Board following the principles expressed in the
Declaration of Helsinki.
CMA 71 microdialysis catheters (30 mm, 0.5 mm diameter,
100 kDa cut-off) were placed into the non-lesioned cerebral cortex
and, whenever possible, to the right frontal lobe. Insertion was via
a cranial access device and through a single burr-hole placed on
Kocher’s point (2–3 cm off the midline; to avoid the superior
In Vivo Secretion of a-Synuclein
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motor cortex). Catheters were connected to the CMA 106 syringe
pump and perfused with CMA CNS perfusion fluid at a flow rate
of 0.3 ml/min. Microdialysis vials were changed every 120 min.
The duration of microdialysis sampling was at least 72 hours.
Samples obtained the first 12 hours of patient monitoring were
excluded from the analysis to eliminate the insertion artifact.
Ultra-sensitive ELISA for a-synuclein
For the sandwich ELISA, the monoclonal Syn-1 antibody (BD
Biosciences), raised against amino acids 15–123 of the human,
mouse or rat a-synuclein sequence, was used as capture antibody.
This antibody recognizes a conserved epitope in human and
rodent a-synuclein (residues 91–99) whereas it shows no reactivity
for the b-o rc-synuclein isoforms [20]. The polyclonal C-20
antibody (Santa Cruz), raised against a C-terminus peptide of
human a-synuclein, was used for antigen detection through direct
conjugation with HRP (Pierce). Each ELISA plate (Corning
Costar) was coated for 24 hrs at room temperature with 0.5 mg/ml
of Syn-1 (50 ml per well) in 100 mM NaHCO3, pH 9.3. Following
coating, plates were stored at 4uC for up to 2–3 weeks. The plates
were washed three times in wash buffer (50 mM Tris-HCl,
150 mM NaCl and 0.04% Tween-20) and 50 ml of microdialysis
sample or recombinant a-synuclein (as standard), appropriately
diluted in TBST/BSA (10 mM Tris-Cl, pH 7.6, 100 mM NaCl,
0.1% Tween-20 and 1% BSA) was added. To allow antigen
binding, plates were incubated at 37uC for 2 K hrs. After washing
three times with wash buffer, 50 ml of HRP-conjugated C-20
Figure 1. In vitro microdialysis to measure a-synuclein. (A) Calibration curve for a novel in-house ELISA for a-synuclein. Serial dilutions of
recombinant human WT a-synuclein were loaded in quadruplicate and read with the new ELISA. Each point represents the mean value measured for
each concentration (n=4, mean 6 SD) as shown in the corresponding table. (B) In vitro percentage recoveries for a-synuclein using the interpolated
zero flow method. Following microdialysis, a-synuclein was measured at various flow rates in human CSF (filled squares) or low molecular weight
secreted a-synuclein species (open squares). The plot is representative of three individual experiments each corresponding to different CSF samples
or low molecular weight preparations. (C) Microdialysis reflects changes in a-synuclein concentration in the sample. Human CSF was either
immunodepleted from a-synuclein (CSF/IP) or spiked with 4 ng/ml of recombinant a-synuclein (Spiked CSF). a-synuclein concentration was
determined by ELISA in the CSF samples (right panel) and the microdialysates (left panel). Immunodepletion of a-synuclein from the CSF showed only
baseline levels of a-synuclein. Spiking with exogenous a-synuclein resulted in a 4.2-fold increase in a-synuclein concentration in the CSF sample and
in a 4.0-fold increase in the microdialysates. The graph represents one of three similar experiments.
doi:10.1371/journal.pone.0022225.g001
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and further incubated for 1 hr at ambient temperature. The wells
were washed and 50 ml of chemiluminogenic HRP substrate
(ultrasensitive luminol reagent, BioFX Laboratories) were added to
each well. The wells were incubated for 15 min at room
temperature and the chemiluminescence was integrated for 1 s.
Immunodepletion of a-synuclein
Human microdialysis samples or human CSF were immunode-
pleted of a-synuclein by immunoprecipitation with 1 mg of Syn-1,
mouse monoclonal antibody (BD Biosciences) as previously
described [10].
Western blotting
Western blotting of striatum homogenates was performed as
previously described [21]. Immunoblotting was performed using
Syn-1 monoclonal anti-a-synuclein antibody (BD Biosciences).
Differences in protein expression levels were quantified using Gel
Analyser software after standardization of all values with b-actin
(monoclonal antibody, Sigma) as loading control. Statistical
analysis was performed using the Student’s t-test, p values of
,0.05 were considered significant.
Results and Discussion
There has been increasing amount of evidence suggesting that
a-synuclein, a protein with mainly cytosolic localization, can be
detected in the plasma and cerebrospinal fluid (CSF) of humans
and in the culture media of neuronal cells [8,10,22,23]. However,
it is generally accepted that the main fraction of proteins detected
in the normal CSF originates from blood and only the 20% of CSF
proteins are brain-derived [24]. Red blood cells have been
identified as the major source of a-synuclein in the blood [25].
Considering the abundance and fragility of these cells, a-synuclein
quantitation in other body fluids, such as CSF, may be
compromised by contamination with intact or lysed red blood
cells. The fundamental aim of the current study was to assess in vivo
the dynamics of extracellular a-synuclein concentration in the
location of its release, the brain. For that purpose, we used in vivo
microdialysis to investigate whether a-synuclein is present in the
ISF of WT and Tg mice that overexpress the A53T mutant form
of a-synuclein (A53T Tg). Two basic advantages of this technique
make it most appropriate for this investigation. First, the
microdialysis samples are devoid of potential substances or
degradation enzymes that could interfere with the final measure-
ment of the target protein. Second, unlike CSF, changes of the
peptide of interest in the microdialysis samples do not follow/
reflect changes of the peptide in plasma [26,27].
The measurement of the concentration of substances in the
extracellular space of the human brain, including macromolecules,
using microdialysis is now well established [28,29,30,31,32].
However, analyzing proteins in microdialysis samples has been
challenging due to the low concentration of the target protein in the
sample of interest and the small amount of ISF often available [14].
To address this issue, we have developed a new, ultra-sensitive
ELISA to determine a-synuclein concentration in biological
samples, including plasma, CSF and ISF. The detection of the
assay is based on HRP-conjugated a-synuclein-specific (C-20)
antibody for the rapid chemiluminometric determination of a-
synuclein, which greatly increases the detectability and reproduc-
ibility of the assay. The detection limit and linear range of the assay
was established by analyzing serial dilutions of recombinant human
a-synuclein (0.03, 0.1, 0.3, 0.9, 2.8, 8.3, and 25 ng/ml) (Fig. 1 A).
Thelimitof quantification(LOQ)wasless than 0.01 ng/ml(defined
as the concentration with a signal/background ratio of 2). The
analytical range of the assay extends from 0.01 up to 25 ng/ml.
Our results show that our new ELISAcan be used for the detection
of full length a-synuclein with high sensitivity and specificity. It should
be noted that, based on the antibodies selected, C-terminal truncated
or oligomeric forms of a-synuclein would not be captured by this
method. In an attempt to assess the applicability of a-synuclein as a
biomarker for PD, various ELISA systems have been developed for
the determination of a-synuclein concentration in biological fluids
[33,34,35], some of which being oligomer-specific [9,22]. Even
though these methods provide high specificity and accuracy, there is
great variability in the amount of a-synuclein quantified in either
blood plasma or CSF. The different ELISA systems employed (in
terms of the antibodies and the detection method used) and the
different protocols for sample collection and processing probably
account for such discrepancies. The a-synuclein specific ELISA
developed in this work offers higher sensitivity compared with
previously described methods. The analytical performance and the
application of this method for the quantification of a-synuclein in
biological fluids (CSF and plasma) will be described in detail in
another study (Emmanouilidou et al, manuscript in preparation).
To ensure a-synuclein detection following microdialysis in mice,
we used A53T Tg mice which, as demonstrated by western blot and
densitometry analysis, exhibit a 3-fold increase in a-synuclein levels
Figure 2. Probe implantation within mouse striatum. (A) Schematic illustration showing the stereotactic placement of a 2 mm-probe in mouse
striatum according to the mouse atlas of Paxinos and Franklin. (B) Photograph of awake, freely moving mouse following insertion of guide cannula
and microdialysis probe.
doi:10.1371/journal.pone.0022225.g002
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n=4) (Figure S1). All mice were used at 8–12 months of age. In our
hands, at this age, A53T Tg mice show no significant variation in
the striatal a-synuclein levels, no development of any motor
phenotype and no abnormalities in the dopaminergic system [21].
a-Synuclein is a 140 aa protein with a molecular weight of
,14 kDa under denaturing conditions. Being a natively unfolded
protein, a-synuclein has been sometimes found to exhibit an
anomalous molecular weight of 50–60 kDa under certain native
conditions [36,37,38]. We, therefore, chose to perform a-synuclein
microdialysis studies in vitro using a custom made probe with a
100 kDa cut off membrane. During microdialysis, a physiologi-
cally compatible perfusion fluid is delivered through the probe at a
low and constant flow rate so that diffusion of solutes occurs in
both directions across the semi-permeable membrane of the probe.
In the case that the perfusion fluid does not contain the molecule
of interest, the concentration in the microdialysate represents a
fraction of the tissue diffusible levels. This is referred to as the
relative recovery [39]. We used the interpolated zero flow method
[19] to define the percentage recovery of a-synuclein through the
100 kDa probe in human CSF or in a solution containing low
molecular weight species of cell secreted a-synuclein (Fig. 1 B).
The mean % recoveries of a-synuclein were similar in these two
solutions at room temperature, achieving a maximum (,40%) at a
microdialysis flow rate of 0.6 ml/min, the lowest rate we tested
(Fig. 1 B). We further assessed whether changes in the
concentration of a-synuclein in the microdialysate directly reflect
changes in the a-synuclein concentration in the sample of interest.
To this end, we performed in vitro microdialysis on human CSF
before and after spiking with recombinant a-synuclein (Fig. 1 C).
a-Synuclein concentration was estimated by our new ELISA in the
starting CSF samples and in the resultant microdialysates. The
increase in a-synuclein concentration by spiking with exogenous a-
synuclein was 4.2-fold for the CSF samples and 4.0-fold for the
microdialysates. Further demonstrating that microdialysis moni-
tors changes in a-synuclein concentration in the solution, a-
synuclein immunodepletion of the CSF using Syn-1 antibody [10]
resulted in barely detectable a-synuclein levels (Fig. 1 C).
After validation of a-synuclein measurement by microdialysis in
vitro, we assessed measurements of a-synuclein in the ISF of WT
and A53T Tg mice in vivo. Guide cannulas were implanted
stereotactically under isoflurane anaesthesia, and 100 kDa cut-off
probes were inserted into the striatum (Fig. 2). Correct probe
placement was verified by Coomassie staining (Figure S2). Probe
insertion may cause acute local injury of the brain area adjacent to
the probe tip, leading to a local compromise of blood brain barrier
integrity. However, due to rapid repair mechanisms, the blood
brain barrier appears to be largely impermeable to relatively large
molecules, such as albumin-bound Evan’s blue dye, within only
30 min of probe placement [40]. Chronic damage, marked by
astrogliosis and inflammation, has been shown to begin 24–
36 hours after probe implantation [19]. To avoid artifacts
originating from local tissue injury, our a-synuclein measurements
in mouse ISF were restricted to a window of 4–8 hrs after probe
insertion. ISF a-synuclein concentration reached stable levels at
6 hours after probe insertion and remained stable even after
Figure 3. In vivo microdialysis in mouse ISF. (A) a-Synuclein
concentration in ISF of Tg mice is stable 6 hours after probe
implantation. Probe was allowed to equilibrate in mouse striatum for
2 hours and three microdialysate samples were collected at 2 hour-
intervals at a flow rate of 0.6 ml/min. a-Synuclein concentration in the
microdialysate samples was determined by ELISA. Stable levels of a-
synuclein were recovered only 6 hours following probe insertion (n=3,
mean 6 SD, one way ANOVA test followed by Tukey’s test,
**p,0.01).
(B) The levels of a-synuclein in mouse ISF remain constant over a period
of 3 days. Probe was allowed to equilibrate for 4 hours before fraction
collection. a-Synuclein concentration in the microdialysates was
measured by ELISA. (C) In vivo concentration of a-synuclein in the ISF
of knock-out (KO), wild type (WT) and transgenic (Tg) mice.
Microdialysis was performed as described in the Methods section. a-
Synuclein concentration was determined by ELISA 6 hours following
probe insertion. a-Synuclein levels were significantly increased in Tg
mice (0.4960.27 ng/ml, n=14) compared to the WT mice
(0.1560.12 ng/ml, n=9). Data are presented as mean 6 SD and
statistics were performed by one way ANOVA test followed by Tukey’s
test (
**p,0.01). As expected, a-synuclein was not detected in the
microdialysates of KO mice (n=5).
doi:10.1371/journal.pone.0022225.g003
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demonstrating that the measured a-synuclein concentration
reflects the presence of the protein in the mouse ISF, and not an
artifact of plasma membrane leakage, the median a-synuclein at 6
and 8 hours was 46% higher than at 4 hours after probe insertion
(comparison performed by one way ANOVA test followed by
Tukey’s test, p=0.01) (Fig. 3 A). This result is important
considering that, if a-synuclein were released due to neuronal
membrane damage following probe placement, we would have
expected to detect high initial concentrations of a-synuclein after
probe insertion (2–4 hours) followed by a gradual decrease at later
time points, but we see the opposite.
We performed in vivo microdialysis in male WT and A53T Tg
mice with a flow rate of 0.6 ml/min. Two-hour fractions of
microdialysate were collected over a period of 4–8 hours following
probe insertion, and measured by ELISA. Figure 3 C summarizes
the mean a-synuclein concentrations in the ISF of these mice
6 hours after probe insertion. The mean ISF a-synuclein concen-
trationwas 0.1560.12 ng/ml forWT (n=9) and 0.4960.27 ng/ml
for A53T Tg animals (n=14). Our ELISA detected no a-synuclein
in the ISF microdialysates of a-synuclein knock-out mice analyzed
in the same manner, strongly validating the specificity of our
method (n=5) (Fig. 3 C). In agreement with a-synuclein levels
determined in the whole striatum by western blotting (Figure S1) Tg
animals also demonstrate a ,3 fold increase in the ISF a-synuclein
concentration compared with WT animals. Taken together, our in
vivo microdialysis data suggest that a-synuclein is physiologically
present in the mouse brain parenchyma.
It has been shown that erythrocytes are the major source of a-
synuclein in blood [25]. In addition, probe insertion could cause
local tissue damage in the brain leading to cell death. To exclude
the possibility that a-synuclein detected in mouse ISF was an
overestimation due to blood contamination or cellular damage, we
initially measured a-synuclein in the plasma of mice that had been
subjected to microdialysis. The levels of a-synuclein in mouse
plasma (,3 ng/ml) were at least 6-fold higher than those found in
mouse ISF. Importantly, we found that a-synuclein levels in ISF
remained constant over a period of 3 days and did not decline over
time (Fig. 3 C). Thus, it seems unlikely that our a-synuclein
readings in mouse ISF originate from plasma oozing into the
brain. In addition, we assessed neuronal degeneration in mouse
striatum after microdialysis using the fluorescent dye, Fluoro-Jade
C [41,42]. Coronal brain sections were double stained with the
Fluoro-Jade C dye, which labels degenerating neurons, and anti-
NeuN antibody which labels the total number of neuronal nuclei.
We found no significant difference in neuronal degeneration in the
striatum comparing the site of probe insertion (ipsilateral site) with
the normal site (contralateral site) (Fig. 4). To this end, we also
assessed the integrity of dopaminergic neuronal fibres in the
striatum following probe implantation. Coronal sections were
double labelled with anti-TH and anti-NeuN antibodies and TH
density was analysed in the ipsilateral and the contralateral sites
using fluorescence microscopy. Local tissue damage caused by
guide cannula implantation was evident in the cortex. However,
striatal TH fiber density was not greatly affected (Fig. 5) suggesting
that probe insertion does not cause significant lesion in the area
where microdialysis sampling is performed.
To further establish the physiological significance of our findings
in mice, we went on to examine whether a-synuclein is present in
human brain parenchyma. In vivo intracerebral microdialysis has
been well established as a bedside technique for clinical
neuroscience providing important information on several neuro-
logical conditions such as traumatic brain injury [43,44] and
seizures [45]. Importantly, intracerebral microdialysis has previ-
ously been used for monitoring amyloid b protein and tau levels as
a marker of axonal injury in humans [30,31]. We analyzed ISF
samples from 8 patients with severe brain injury who were
admitted to the ICU and had intracranial monitoring for clinical
Figure 4. Probe insertion does not cause significant cell loss in mouse striatum. Coronal striatal sections obtained after microdialysis
stained for the presence of degenerating neurons with the fluorescent dye, Fluoro-jade c (A and C). Arrows indicate degenerating neuronal nuclei at
the guide cannula insertion side (ipsilateral side) and the opposite, non-treated side (contralateral side). Sections were co-stained with NeuN (C and
D) to mark neuronal nuclei. Images were obtained with fluorescence microscope under 20x magnification, scale bar, 50 mm.
doi:10.1371/journal.pone.0022225.g004
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minimize the risk of infection. Microdialysis sampling in human
brain have also been reported for periods up to 6 days with no
reference of side effects due to inflammation [29,44,46]. Two
microdialysis samples from each patient were randomly selected
from 24 to 36 hours after probe insertion and assayed for a-
synuclein with our new ELISA. a-Synuclein was readily detected
in the ISF of all patients (Fig. 6 A). We next performed in vitro
microdialysis to estimate the % recovery of a-synuclein through
the 100 kDa CMA 71 probe that was used to obtain the human
microdialysates. Using the interpolated zero flux method [19], the
% recovery of a-synuclein in human CSF spiked with known
concentrations of recombinant a-synuclein (2–16 ng/ml) was
found to be ,80% at a flow rate of 0.3 ml/min (data not shown).
After correction for this % recovery, a-synuclein concentrations in
human ISF varied from 0.5 to 8.0 ng/ml (n=8). None of the
patients analysed had a diagnosis of PD or other dementia,
suggesting that the presence of a-synuclein in human brain
parenchyma is not disease-related. Although the probe was
inserted in a healthy brain area, away from the injured side, one
cannot rule out the possibility that a-synuclein levels we measured
in the human ISF are not affected by the overall brain status.
Various parameters, such as synaptic activity and metabolism,
may affect the levels of extracellular a-synuclein in humans. In this
sense, the values obtained in our study do not represent control
reference measurements of a-synuclein but rather prove the
presence of the protein in the human brain.
To verify that the ELISA values obtained from human ISF
correspond to true a-synuclein concentrations, we performed two
sets of experiments. First, serial dilutions of a human ISF
microdialysate having a relatively high a-synuclein concentration
were prepared and assayed by ELISA. As expected, the
chemiluminescence obtained from each dilution was linearly
correlated with the dilution factor of the sample (Fig. 6 B). Second,
human microdialysates from two patients were immunodepleted of
a-synuclein using the Syn-1 antibody [10]. a-Synuclein levels were
compared before and after immunodepletion. This resulted in
almost undetectable levels of a-synuclein (Fig. 6 C). Taken
together, these experiments indicate that our ELISA readings
represent changes in the amount of a-synuclein in human ISF
collected by in vivo microdialysis.
Inconclusion,ourdatasuggeststhata-synucleinisphysiologically
released into the interstitial fluid of the brain in mice and humans,
and they further suggest as role for secreted a-synuclein under
physiological and pathologic conditions. It is clear that a-synuclein
is a key molecule in familial and sporadic PD. Most notably,
relatively small (50%) increasesin its levels are sufficient to cause PD
in humans, and it accumulates early in the brains of patients with
sporadic disease. This study demonstrates direct evidence that
soluble, ISF a-synuclein can be measured in brain parenchyma in
vivo. This secretable form of a-synuclein may be biologically
important,sinceitcould exertparacrine effectson neighboringcells.
The physiological role for extracellular a-synuclein remains to be
identified. Maintenance of the intracellular steady state concentra-
tion of a-synuclein is considered a key challenge for neuronal
homeostasis, and elevated total brain levels of the protein have been
directly linked with PD pathogenesis. It is possible that a dynamic
equilibriumbetween intracellular and extracellular a-synuclein may
exist ensuring normal functioning of neuronal cells. In this respect,
dysfunctions in the mechanism(s) regulating extracellular a-
synuclein levels, such as mechanisms of secretion, re-uptake or
extracellular clearance, may affect neuronal survival. Increases in
extracellular a-synuclein could trigger toxic oligomer formation and
result in inflammatory glial activation [47], finally leading to
neurodegeneration. However, any oligomer formation might be
expected to occur intheconcentrated milieuof the cytoplasmrather
than in the more dilute extracellular fluid, and it will now be
important to ascertain whether soluble oligomers arealso released in
vivo. According to Braak [48], the progression of PD symptoms
could be due to spreading of misfolded a-synuclein along poorly
myelinated axonal pathways. It was recently shown in postmortem
studies that embryonic stem cells grafted into the brains of people
with PD exhibited Lewy body pathology and a-synuclein
accumulation [13,14]. Furthermore, Hansen et al. recently
demonstrated that a-synuclein transmission in vivo depends on
endocytosis [15]. These findings suggest the possibility of an a-
synuclein host-to-graft propagation process in PD. The existence of
secreted a-synuclein in the living brain as validated by our work
supports this hypothesis. Much cell biological work will now be
required to elucidate the non-classical secretory mechanism(s) of a-
synuclein in vivo. We believe that our approach will allow the
systematic investigation of these mechanisms and also provide
insights to understanding PD pathogenesis. In this respect, down-
regulation of extracellular a-synuclein levels could be a potential
target for the development of treatment strategies for PD.
Figure 5. Striatal neuronal fiber density is not affected by
probe placement. Representative coronal sections showing the side
of probe insertion (ipsilateral side, E-H) and the opposite, control side
(contralateral side, A–D). Sections were double stained with TH (green)
and NeuN (red) and visualized under low 2.5x magnification (A, B, E, F,
scale bar, 1 mm). Confocal images C, D, G, and H represent enlargement
of the areas in boxes (40x magnification, scale bar, 50 mm). White
arrows indicate tissue damage caused by guide cannula implantation.
doi:10.1371/journal.pone.0022225.g005
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Figure S1 a-synuclein levels in the striatum of WT and
A53T Tg mice. Representative immunoblot of striatum
homogenates from WT and A53T Tg mice (n=4) analyzed for
the presence of a-synuclein using the Syn-1 antibody. b-actin is
used as loading control. Quantitative densitometric analysis (right
panel) demonstrates a 2.861.2 fold increase in a-synuclein
striatum levels of Tg mice compared with WT mice (n=4, mean
6 SD, independent t-test, *p,0.05).
(DOC)
Figure S2 Probe placement in the mouse striatum.
Representative image showing probe placement in mouse striatum
according to the mouse atlas of Paxinos and Franklin. Intense
staining depicts location (arrows) of the probe membrane through
the area of striatum.
(DOC)
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